Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

The commenter supports the creation of a safe, regulated pathway for compounded peptides to ensure patient and physician access to these treatments. They argue that restricting access could drive patients toward unregulated markets and increase costs for those with chronic conditions.

The commenter, a patient who has benefited from physician-supervised peptide therapy, opposes the potential restriction of access to compounded peptide therapies. They argue that such restrictions could limit individualized treatment options and potentially drive patients toward unregulated sources.

A patient who successfully used peptide therapy to lose weight and improve their health supports the action. They urge the FDA to consider real-world patient experiences and preserve access to these therapies while maintaining safety standards.

An individual consumer supports the creation of a safe, regulated pathway for compounded peptides. They argue that providing regulated access helps preserve the patient-provider relationship and prevents patients from seeking unregulated, potentially unsafe alternatives.

The commenter, a private individual, supports the inclusion of peptides on the bulk drug substances list to increase accessibility for patients. They share personal success stories regarding weight loss and inflammation reduction through peptide use.

An individual shares their personal success with peptide medications and advocates for safer, domestic access to these substances. They support the action as a means to provide safer alternatives to unregulated overseas sources.

An individual who uses peptides and NAD+ for personal health benefits argues that everyone should have access to these substances. The commenter supports the action as it relates to making these life-changing substances more accessible.

An individual patient who successfully used peptide therapy to manage PCOS and insulin resistance supports the action to ensure patients maintain access to safe, regulated, and provider-guided therapies. She argues that restricting access through licensed providers may push patients toward unregulated sources.

A board-certified RN and Family Nurse Practitioner argues that the FDA should preserve access to compounded peptide therapies for individualized patient care. The commenter emphasizes that compounding is essential for patients who do not respond well to conventional medications and highlights their own successful clinical and personal experience with these treatments.